AzTrials
AzTrials

Blood Component TransfusionNCT01187030

Appropriateness of Frozen Plasma Use in Canada

An observational study of Blood Component Transfusion, run by Ottawa Hospital Research Institute.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

There is little evidence to guide the current use of Frozen Plasma. Despite this, over 260,000 units of frozen plasma are transfused in Canada annually. Based on the limited published data available, the pattern of practice for Frozen Plasma transfusions is highly variable and an important number of Frozen Plasma… Read more about this study

Who is it for?
Ages 16 years and older
Conditions the study is for
Blood Component Transfusion
How many people
2,580 participants
Where
No sites listed yet
Study dates
May 2008to Mar 2011
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 16 years and older
  • All sexes
  • No healthy volunteers
  • Child, Adult, Older adult

Study population: Patients at 10 academic medical centres (17 hospitals) across Canada

Who may be able to join

  • All subjects receiving frozen plasma or PCC transfusions

Who cannot join

  • No subjects excluded -

About this study

There is little evidence to guide the current use of Frozen Plasma. Despite this, over 260,000 units of frozen plasma are transfused in Canada annually. Based on the limited published data available, the pattern of practice for Frozen Plasma transfusions is highly variable and an important number of Frozen Plasma transfusions appear to be inappropriate. Given inappropriate use, it is inevitable that a percentage of patients experience unnecessary and potentially life-threatening adverse transfusion reactions. Current guidelines for Frozen Plasma offer little help in guiding specific clinical decisions as their recommendations lack sufficient clinical details. This lack of detail also hinders the utility of these guidelines to help monitor and improve clinical practice. Further research examining Frozen Plasma transfusions including an understanding our current use is critical to improve the utilization of this valuable and limited resource.

Read the detailed description

Objectives: We will (1) systematically review the evidence for the use of Frozen Plasma transfusions, (2) establish appropriateness ratings for all clinical scenarios for which Frozen Plasma is transfused, and (3) perform a 3-month prospective study to understand the current use and the appropriateness of use of Frozen Plasma in 12 Canadian academic centres.

Methods and Analysis: Following a well established methodology to evaluate medical therapies developed at RAND/UCLA, the investigators will purposively employ different epidemiologic techniques to assess the current use and appropriateness of Frozen Plasma transfusions in Canada.

First, we will undertake a thorough systematic review of the evidence for the use of Frozen Plasma across all indications.

The RAND modified Delphi methodology will then be used to determine the appropriateness of transfusing Frozen Plasma across a comprehensive set of clinical scenarios. A panel of 9 experts representing relevant clinical specialties will use the evidence from the systematic review to determine the appropriateness ratings (an ordinal scale of 1-9) for each clinical scenario.

Subsequently, we will undertake a prospective cohort study of all episodes of Frozen Plasma transfusions (approximately 5000 episodes) at 10 Canadian academic centres (17 hospitals) using the appropriateness ratings. Trained research assistants will identify all transfusion episodes via the blood bank and perform a chart review to obtain demographic variables (age, sex, weight), clinical variables (diagnosis, coagulopathy, indications for frozen plasma transfusions, other blood product transfusions), and laboratory (pre and posttransfusion coagulation tests) information. These data will allow mapping of each transfusion event onto a specific clinical scenario rated by the expert panel and the assignment of an appropriateness rating. We will also determine the total number of patients and the number of patients for each of the largest user groups of Frozen Plasma at each hospital. The primary outcomes for the prospective cohort study, the proportion of inappropriate transfusions (appropriateness) and the proportion of patients transfused (overall utilization), will be initially examined using descriptive statistics. Using hierarchical modeling, a logistic regression analysis will be used to examine the proportion of inappropriate transfusions while controlling for indication, hospital, and patient factors. For the analysis of overall utilization of Frozen Plasma, a chi-square analysis will be used to compare the proportion of patients transfused in the largest user groups at the different hospitals. A secondary analysis will examine the dose of Frozen Plasma transfused.

Generated Research: From the systematic reviews, appropriateness ratings, and the results of the cohort study, we will have summarized the evidence supporting the use of Frozen Plasma, produced detailed clinical guidelines outlining the appropriate and inappropriate indications for Frozen Plasma and provided an understanding of the variation in use and appropriateness of Frozen Plasma. Each of these elements can then be used by hospitals in Canada and elsewhere to improve the current use of Frozen Plasma. Understanding of the variation in Frozen Plasma will allow for a framework to improve transfusion practice and identify those areas of Frozen Plasma use that merit the greatest attention for further research.

Keywords
Frozen Plasma, Fresh Frozen Plasma, Prothrombin Complex Concentrates, RAND UCLA, Modified Delphi Methodology, Expert Panel, Appropriateness Rating

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. The primary outcome for the appropriateness of Frozen Plasma transfusions will be the proportion of appropriate transfusion episodes.

    Each transfusion episode will be the unit of analysis as a single patient may receive both inappropriate and appropriate transfusions.

    Measured: 2 months

Secondary outcomes (1)
  1. The number of units transfused per patient will be the secondary outcome.

    The investigators consider whether or not a patient received either Frozen Plasma or a prothrombin complex concentrate as the most clinically important outcome. The investigators will also collect data on the total number of patients in hospital for the study period. This outcome is also important as differences in transfusion dose will have an important impact on the cost of Frozen Plasma and prothrombin complex concentrate transfusions and will not be captured in an analysis looking solely at the proportion of patients transfused

    Measured: 2 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted23 Aug 2010 (estimated)
  2. Study startMay 2008
  3. Primary completionMar 2011
  4. Study completionMar 2011

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
2,580 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT01187030
Sponsor's protocol ID
200766101
Status last verified
May 2012
First submitted
20 Aug 2010
Last updated
23 May 2012
Results posted
No
Data monitoring committee
No

Questions about this trial

What is this clinical trial studying?

An observational study of Blood Component Transfusion, run by Ottawa Hospital Research Institute.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 23 May 2012. Status can change between updates, so confirm with the study contact before making plans.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

The primary outcome for the appropriateness of Frozen Plasma transfusions will be the proportion of appropriate transfusion episodes. (time frame: 2 months). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 23 May 2012.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in